Martin Klein1, Heřman Mann1, Lenka Pleštilová1, Josef Zámečník2, Zoe Betteridge3, Neil McHugh4, Jiří Vencovský5. 1. Clinical Department, Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague. 2. Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic. 3. Department of Pharmacy and Pharmacology, University of Bath and. 4. Department of Pharmacy and Pharmacology, University of Bath and Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK. 5. Clinical Department, Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, vencovsky@revma.cz.
Abstract
OBJECTIVES: Immune-mediated necrotizing myopathy (IMNM) is characterized by the predominant presence of necrotic muscle fibres in muscle biopsy and variable response to immunosuppressive treatment. The aims of this study were to analyse the temporal trend of IMNM incidence in our centre over the past 10 years and to explore the role of statins as possible causative agents. METHODS: A retrospective evaluation of muscle biopsy results, clinical and laboratory data, including antibody associations of all patients with idiopathic inflammatory myopathy newly diagnosed between 2004 and June 2014, was performed. Available sera were tested for the presence of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) autoantibodies. RESULTS: Of 357 biopsied patients, 233 fulfilled criteria for inflammatory/immune-mediated myopathy, including 27 (11.6%) classified as IMNM. There were no patients with IMNM diagnosed between 2004 and 2007; subsequently, two to three cases of IMNM per year were seen during the period 2008-11, with a substantial increase to 18 cases (66.6% of all IMNM biopsies) in 2012-14. Thirteen of 27 patients (48%) had a history of statin use, 11 (85%) of whom had positive anti-HMGCR antibodies. There was no IMNM patient without a history of statin use who was anti-HMGCR antibody positive. CONCLUSION: Our data show an increasing incidence of IMNM, which is mainly accounted for by anti-HMGCR-positive IMNM associated with the use of statins.
OBJECTIVES: Immune-mediated necrotizing myopathy (IMNM) is characterized by the predominant presence of necrotic muscle fibres in muscle biopsy and variable response to immunosuppressive treatment. The aims of this study were to analyse the temporal trend of IMNM incidence in our centre over the past 10 years and to explore the role of statins as possible causative agents. METHODS: A retrospective evaluation of muscle biopsy results, clinical and laboratory data, including antibody associations of all patients with idiopathic inflammatory myopathy newly diagnosed between 2004 and June 2014, was performed. Available sera were tested for the presence of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) autoantibodies. RESULTS: Of 357 biopsied patients, 233 fulfilled criteria for inflammatory/immune-mediated myopathy, including 27 (11.6%) classified as IMNM. There were no patients with IMNM diagnosed between 2004 and 2007; subsequently, two to three cases of IMNM per year were seen during the period 2008-11, with a substantial increase to 18 cases (66.6% of all IMNM biopsies) in 2012-14. Thirteen of 27 patients (48%) had a history of statin use, 11 (85%) of whom had positive anti-HMGCR antibodies. There was no IMNM patient without a history of statin use who was anti-HMGCR antibody positive. CONCLUSION: Our data show an increasing incidence of IMNM, which is mainly accounted for by anti-HMGCR-positive IMNM associated with the use of statins.
Authors: Eleni Tiniakou; Iago Pinal-Fernandez; Thomas E Lloyd; Jemima Albayda; Julie Paik; Jessie L Werner; Cassie A Parks; Livia Casciola-Rosen; Lisa Christopher-Stine; Andrew L Mammen Journal: Rheumatology (Oxford) Date: 2017-05-01 Impact factor: 7.580
Authors: Takayuki Kishi; Lisa G Rider; Katherine Pak; Lilliana Barillas-Arias; Michael Henrickson; Paul L McCarthy; Bracha Shaham; Pamela F Weiss; Iren Horkayne-Szakaly; Ira N Targoff; Frederick W Miller; Andrew L Mammen Journal: Arthritis Care Res (Hoboken) Date: 2017-07 Impact factor: 4.794
Authors: O Shovman; B Gilburd; C Chayat; A Dortort Lazar; H Amital; M Blank; C Bentow; M Mahler; Y Shoenfeld Journal: Immunol Res Date: 2017-02 Impact factor: 2.829
Authors: Sarah L Tansley; Stefania Simou; Gavin Shaddick; Zoe E Betteridge; Beverley Almeida; Harsha Gunawardena; Wendy Thomson; Michael W Beresford; Angela Midgley; Francesco Muntoni; Lucy R Wedderburn; Neil J McHugh Journal: J Autoimmun Date: 2017-06-26 Impact factor: 7.094